AADI - Earnings call transcript Q1 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to the Aadi Bioscience, Inc.

First Quarter 2021 Earnings Conference Call. [Operator Instructions]. It is now my pleasure to introduce your host, Andrew Quan, VP of Business Development and Corporate Strategy. Thank you.

begin. may You

Andrew Quan

Founder, development to updates; Officer, Delaney, will Quarterly like on to provide first of Neil will the call metrics; give who Scott I Itri, quick M. Loretta Officer, a Financial who Call welcome for will Bioscience overview early Desai, are Bioscience who Results from and quarter; Officer, forthcoming this us and Operating provide of QX Chief Aadi us walk priorities CEO, today Giacobello, Chief will Brendan would the clinical Aadi an everyone President Chief through Dr. XXXX. the and our commercial uptake and quarter. Medical who commentary financials overview With

forth everyone Before including and include we can of forward-looking result materially various filings website Commission, www.aadibio.com. by Securities that call this statements Exchange risks at statements. set and make and annual of forward-looking from with uncertainties Risk implied a get results will conference factors, at the on quarterly those be started, and those we section I could remind our Factors or in any events as to statements our on or Actual www.sec.gov, or differ other found expressed would the like

over be forward-looking We In date. or turn statements. update views relied subsequent not Neil. this any XX, upon addition, any views only call representing of on and disclaim let any any our XXXX, as With forward-looking call me obligation as should revise represent statements made the May of today, specifically as that, to to our

Neil Desai

morning, Good everyone, thank and Thank joining. you you, for Andrew.

talent as launching year. our transitioned integrated commercializing Aadi of patients biopharmaceutical on this quarter begin first known FYARRO, promise mTOR napsurolomus, successfully as PRECISIONX operations transformative $XXX and organization. first our in in continued for R&D of building known We product, a we have tumor-agnostic for advanced our continue million, and company into fully registration-directed delivered new all approximately PEComa, We our February to cash of to quarter, XXXX. strong is high-quality first albumin-bound expected malignant commercial and enrolling also the XXXX the March. trial XX an into at our in In areas inhibitor, of company, funding The Bioscience. remained our was recruitment position And on and

long-term only XXX indication. ultra are malignant first patients malignant approved are key to and maximize and inhibitor launch the clinical this strengthen potential priorities parameters is around and mTOR for first now Even new XXX with malignant advanced encouraging. specifically further an commercial sarcoma patients for in the FDA-approved to XXXX in only create and to in U.S. the of indicated value. the Our our PEComa ability PEComa the FYARRO FYARRO year advanced to PEComa for viral per though advanced rare is treatment

$X.X this still and for we further. to our to quarter, among that make PEComa. will executing MPEG have the achieved as great FYARRO to permanent commercial adoption million Brendan weeks say launch, sales physicians. in we level very and sentiment unmet physicians, thank have in is July we should Early evidence We Brendan be even XXXX, program like and We FYARRO very in clear in patients of need. commercial entire preferred of demand. with recently, both the and I In a has trial high their physicians of we his moments. And for received more discuss patient products, would first expanded strong X by a part X, will which that awareness effective patients easier J-code are guideline and we and the NCCN demand a highly favorable FYARRO encouraging pent-up this the been well in a clinical the a recommendation will since cancer secured While clear have the to early lot highlighting treatment interest quarter, first payer And by a FYARRO. transitioning FYARRO received and In launch team of prescribing are performance for of treating this end alike. such a net Brendan on topic quick to this believe dire it difficult-to-treat attribute access in start. pleased general, we with for differentiated product few is FYARRO and

on very in are we the front, March Napserolomus for many sirolimus TSCX are open to types. first has tumors. progress trial or potential to and application This TSCX high-quality enrolled working our our R&D clinical registration-directed the broaden pleased our solid X, MAP alterations of across patient with the PRECISION future significantly On We tumor different in tumor-agnostic sites. trial steadily in

partnerships enrollment augmenting and via community further networks. oncology NGS providers are with We

recruitment our place, patient feel confident intention strategies these in XXXX complete first in to in and study PRECISION the half XXXX. about from data preliminary of With present the we X

our job in PRECISION In also will goal her running. give to trial clinical or the kick clinical new in with new team shortly. this a Loretta and agent maxerolymus, addition X getting off has She treatments combination the options XXXX. to additional for color topic single terrific the team up studies done PRECISION on is evaluating with X trial, and

we have of addition, and of areas company in our all high-quality recruitment organization. quarter, continued expansion the first the in talent In

We office industry oncology established new national recently a Morristown, Northeast for and New in the Jersey, talent. a have hub expertise in

firing are efficiently value is need while targets patients unmet the for novel FYARRO we helping the many all access maximize gain drug and this now pathway. with of to summary, to working our the that Aadi cylinders In and shareholders, so to important on officially into And bicoastal.

Brendan? in as Our discuss goal in company detail. is now commercial launch the Brendan greater establish precision to and indeed will leading oncology. Aadi our progress

Brendan Delaney

and quarter that as company time partial is first to stage from Neil. commercial insights available important regarding became well is results on XX. early commercially of FYARRO FYARRO as an It in a you, launch I'm Bioscience, PEComa. consider today It to as Thank February Aadi's at the share Aadi exciting thrilled

that results a selling shared time today X-week the days period. will reflect over So be XX

are be in encouraged on initial option. the days are patients Underlying discussing commercial early important We launch, Even we by very the access this battling so to trends call trends FYARRO. early, of the truly the are treatment PEComa will today. needed the our success of though we who uptake

help of of launch this product has in been available our are that February they people is meaningful represent most market as by on year, launch. strategic driven XX imperatives. Since humbled We this story making to it success X these the the

to FYARRO accomplish brand we a to care First, goal, need frontline In metrics. share in awareness of early to as brand quickly to accelerate is setting. ability too to meaningful our PEComa that standard success. awareness paramount is establish the It order

of awareness breadth us and metrics FYARRO ordering on the are centers treatment tracking However, institutions uptake leads that our target. across early the brand to believe

and group been in leading to factors: when continue FYARRO and have of strengthen these manage our have we this managing need since early effectively in as ensure expressed the we a health we to differentiate on ultrarare the and users PEComa. a leaders, achieved overall throughout focused that first first-time have teams experience of Based We company these using have million And increased volunteered small expanded multiple visibility the the expectations early clinical feedback net when educating treatment commercial few for Aadi our And sarcoma it establish new launch, positive the transitioned and and from engage adopters, the within by and on continued early program encouraging X partnerships treated attribute to care launch, AMPECT to launch, on $X.X Aadi oncology. appears experience. treatment patient prescribers sarcoma of initiate trial, they despite in access Piccoma our in In March. drug. a successfully a a Second, PEComa third, Bioscience Throughout the industry weeks can to as key will advocacy through nature patients Based First, within community. space. trusted cycles were experience, precision sales several opinion product we the therapy. of first performance ongoing weeks positive the providers to patients leader

the intervening had demand our patient between approval building anticipation pent-up been XX, XX, February Additionally, on on commercial period during launch product November of and in the availability.

steady-state Lastly, we clinical we profile volume, build positive. as been specialty patient we Based to reach dissipate demand. to on FYARRO as early patient observed distributors the reacting the early reaction inventory were more expect launch very some to feedback, has that

seen the as as disease AMPECT duration response In the response reported the the labeling differentiating. in addition are rate reported of overall control to trial registrational from data highly and the rate,

Aadi Although with in first-line recent early setting PEComa market can that share XX%. guidelines advanced estimates the treatment research for exceeded the only reflect for in preferred treatment option the in by revealed FYARRO the unreliable, U.S. to intent conducted market early of NCCN malignant PEComa. update be prescribe as further for Momentum FYARRO quarter FYARRO the was the first to rapid supported oncologists

of sarcoma to cancer accounts, centers FYARRO X rare As the XX% has form the accounts. sales we academic has first policies ordered in the prescribers product. our the had both of we treatment with a treating of high focus policies be of States, large advanced adopting reflected XX% need specifically, from in unmet that strong weeks which for the approximately and coverage sense top physicians centers. potential Recognition sarcoma, large of been is case, PEComa academic expected to in paves urgency, of profile launch, March represent removes happy place to XX, detailed and formal the payers within with there strategic also for medical centers the as of broad XX accounts have that adopting team malignant access. through I'm FYARRO. Because academic excellence that in have Having PEComa report coming the were approximately patient been for XX the also barriers way these on early proven coverage formal payers a and a has United of with the which the orders clinical setting. have of representation early More

March lives formal the welcome and other oncology authorization pay announced we recently, the I'm coverage FYARRO the during of that the vast launch, that information is majority performance a that prior also first to news been application that to which As policies pleased commercial CMS FYARRO metrics product prescribing a streamlines restriction. of to exceeding will FYARRO, the quality for are as of have of market review impressive, J-code launches. they in effective weeks happy X time to XX, care. Very that we for see XX% implementing I'm we or of X. coverage major permanent approved States is monitoring payers the of J-code policy. covering United for report adopted reviewed as of sites position report equally permanent all also our a with without a This across become July reimbursement new have

resources with novel patients we've support rapid AadiAssist, patient this and access a of FYARRO, suite strong available payer happy we Fiera All mTOR resulted excited now we launch patient approval. through progress the of in inhibitor. summary, access patient our that strong this In for the since made to progress since have combined PEComa of has are are FDA about program,

tremendous I would a it success. Bioscience extend you early my sincere to for another this making to Loretta, Aadi thank turning over colleagues all launch to Before like

on Now Loretta you program. our an update clinical will give

Loretta Itri

Thank you, fronts report proud last progress important quarter. Brendan. the several in on I'm to

rapidly group staffed. have completely conduct the nearly a we oversight our trial fully strengthened ongoing This division while has clinical up of hiring significantly trial sites First, clinical providing to for and trial. all on set tumor-agnostic with launching enabled and high-quality facilitate development recruitment patient talent precision us functions R&D operational appropriate

at least first in Cancer by goal centers our United Second, trial MD Dana XX end and Farber this of enrolled of we States Institute cancer initiating and great towards study Center, this the progress in major Anderson have patients the year. Cancer have at our the made the in

please. slide, Next

trial, enrollment Foundation including and providers, strong with ensure next-generation we sequencing PRECISION to in order the leading the in Third, have X partnered Tempus. Medicine

TSCX other X the We to are or utilizing alterations, with TSCX appropriate physician their PRECISION are working networks who patients patients NGS participation closely also these of and helping recommend providers, trial. to and in identify with

please. slide, Next

than rapidly efforts. to study. academic Importantly, our Oncology annually. we identified individual Using physician with activate for USO's enrollment we patient oncologists a well in treatment This of centers leverage X.X is locations formed million who partnership us in X,XXX STAR have will program, the more target U.S. qualifies help network can than patients community as the sites as clinical includes entire its also additional centers once participating trials more than more the cancer partnership that XXX and

Taken oncology by enrollment next full enrollment identifying these this augment within the drive benefit by academic from patients trial series both should practices believe participation study. may X will enrollment activities together, targeting trial their TSCX and rapidly or the with of TSCX into efforts focused XX PRECISION this appropriate We alterations, into and community-based months. that and expediting who patient

Next slide, please.

TSCX As an a is evaluate and to TSCX adolescent The Aadi trial multicenter, or to evaluate of solid this a study. or with genes. patients, study trial the the nabseromas. in independent PRECISION X trial will received NAB FDA. here XXX pivotal designation TSCX has trial The of reminder, sirolimus indication with approximately evaluate from track fast separately alterations PRECISION each design will outline of tumors inactivating the have alterations. adult either X X arms patients open-label, pathogenic XX is patients for tumor-agnostic in harboring The TSCX

expanded to The Cancer X% findings of first TSC Aadi, alterations. Annual this the TSCX in of This patient X% targeted these patients. Meeting Academy The one carry These was solid Conference. patients March or within from and a and at the confirmed Research tumor was the renders the all work occurring States XX,XXX approximately Last initial XXXX. alterations United presented frequency supported gene largest treated by for the at oncology, categories month, TSCX of genetic were demonstrated the PEComa. to an X incidence of known estimates PRECISION compelling NAB safety in data in give timely of in of a American physician both sufficient been and shown this has TSCX, grant on alteration of already The proof case, enriched to trial has given the common profiles unusual us especially It agent clinical malignant encouraging. principle additional practice. enroll number tumor both to ability approved confidence that of are type, newly regarding well-defined patients from Navsaromes in our a within the the advanced in a manner. is pharmacology group X complete of in reception community a patients specific is This sirolimus have and that oncology and

Although that XX% reported alterations, exploratory, Oncology, XX in that in advanced study inactivating patients PEComa a and of results is with the which a patients. impressive a high TSCX or durability. of obtained patients is or percentage of XX% with advanced patients TSCX of with partial were response a analysis evaluable response were seen in in X the PEComa, of achieved was or known with biomarker AMPECT registrational TSCX or the impressive who as patients Clinical TSCX alteration Journal of expressed malignant Indeed, XX XX complete malignant

and different been other have will with we other community. opportunities evaluate single financial very patient from in suggestions Scott to either carefully have opportunities combination NAB or for to populations. receiving continue by the indications, now interesting it a we the turn believe expand to across over many use are I inspired there We potential for therapies agent We sirolimus update. been

Scott Giacobello

now XX we cash quarter revenue plans, morning. results to We Total quarter good and February entirely the $X.X Based of operations ended of more following will on and equivalents was filed of for XX-Q be into of Loretta, XXXX. fund sales million. FYARRO with be product XXXX. current financial expect the quarter provided discussion launch. I'll consisting our equivalents $XXX.X March cash the today. net million, and the for in cash later XX, A to cash our Thanks, ended results detailed summarize

to $X.X product for and mentioned, patients sales consisting FDA costs year who demand the primarily prepare Selling, PRECISION prior substantial AMPECT inventory increase the Research of incurred the of related related Cost period initiation sales primarily launch organization. during Resulting EAP specialty of the for costs number distributors. the prior $XX.X development to the commercial quarter, the to of for you, the development the patient expenses $X.X trial at the general to in Neil. is of was the FYARRO the year million loss $X.X million inventory I'll quarter. for incurred. approval, This related year for and quarter launch million expenses build-out commercial transitioned Thank marketing timing increase commercial to in up and is expensed million were the result $X.X product the mainly to trial FYARRO on and quarter, back hand and to to in build-out compared the were FYARRO. to the Brendan approval and prior pent and and million infrastructure, is quarter. between expenses This $X.X increased to the quarter amounted our from royalties sales. due R&D as reflects million increased quarter As call X this the of operations quarter. build which research prior and of administrative of by in initial the net $X.X for to million compared expenses to favorably impacted now and Cost

Neil Desai

you, communities, very encouraged summary, by by Thank of Scott. the we FYARRO In we physician the with trend acceptance the and remain early far. so seen patient and pleased are

enrollment intently other PRECISION maximizing to application forward cancer are focused X, treat in and of look the We types. [indiscernible] on to

focus this Before we entire open Aadi for impressive past hard a the and over work call moment at and thank like for take quarter. Bioscience Q&A, team here execution I'd the to their

on the successfully, to launch, on that, first we I'd execution our the today, call PRECISION commercial R&D we quarter Looking continued of and our side, are trial. well open questions. to our With for forward, confident X of FYARRO momentum operator, the tumor-agnostic like I'm partial on our continue to building both positioned reported execute that

Operator

[Operator Instructions].

with Boris from Peaker comes question first Cowen. Our

Boris Peaker

hear Congratulations guys? the progress. on Can you me

Scott Giacobello

Yes, can Boris, hear. I

Boris Peaker

Fantastic.

question do estimate approximately my have the an revenue demand much you an the inventory of that comment was So end-user you build. instead? first or is you of mentioned part how Can estimate

Neil Desai

So that. quantify - is you Thanks, yes, oncology Boris. it's this in have that A is Brendan, Yes, Boris, say launch expected hard like Brendan Neil. would What usually, Delaney up would obviously, that would inventory. to question, please? answer to answer an it. I that I built can and some it's you comment

little early I you're here, because It's think think above of weeks what reacting expect. to of couple I we on, So right? levels to I don't And volume distributors would that's a of part though, higher-than-anticipated inventory probably hand of a on that's specialty think we quantify, see. hard bit that there's it. multiple

For example, to a of academic carrying addition by done some which distributors. was the as the remarks, in institutions, of you as lot heard well many specialty the ordering, in prepared are inventory

introduces patient launched it's in the in in demand would in quantify seeing I it. and say we're level November just approval trying what of underlying So demand. extrapolating another February. complexity where pent-up excited situation FDA in ultimately pretty received say the or also will -- and to as But launched about I we're we

I well, as time and to, contributed that I exciting that also certainly think start at patients were building here. an think,

Boris Peaker

how on And treatment? long to Great. patients just remain these anticipate you do

Brendan Delaney

Again, hard Boris. to say,

only as we kind this That's at but reorder encouraging. it's we it's the really that certainly that's to of part, I metric in But is But we're a early, can... next be see. the far this ahead loose encouraging difficult, But I encouraged patient-level or very I don't the early reordering, what when data to I it's but going for for best patterns, months individual we point, see duration think accounts not right? we what track determine. by which think think patients. to have that ordered But see as

Boris Peaker

for is the what in in for of should PRECISION you of X, patients Great. be first you the update? be year. And terms we question, last on first next expecting that mentioned interim the going my any or to Can half of other term comment expectations in number

Neil Desai

can is I that Neil. take one. this Boris,

enrolling. So as just begun this trial we've said has before,

the visibility the of come will so course, many cetera, enrollment that will, And the later more et in centers year rate, but get as online. into come,

exact sort that the first about a we half, of predict of the But expect at update meaningful confident that would to yourself, of of number we in like number feel the exactly patients nature terms the that investors the so look it's of said, in you the and So patients. future provide of drug. can analysts data hard the and

information tumor In other of of been some the types have color probably we or the types that we would analysis would that some enrolled give about in give study different terms a trial. and provide, the information that keep these early exactly time. the We this right now nature registration in this in But at that also outcomes again, patients the a bit to outcome. is is mind predict on the should of

are importantly, to very And in we we're PEComa, for and approved And that being put careful any have marketed is how we some drug situation unusual be promotion data there we the and so that out advanced have limitations but construed. an thereof. type there secondly, can be off-label with

give with investors course, is the to goal, those of what we're at seeing early in So on. look the a trial limitations,

Operator

question next Demir Ladenburg from comes Our with Thalmann. Ahu

Ahu Demir

have on X. progress. PRECISION the side, on then we'll Congratulations into questions the the go commercial X I

payers considering the aspect? side, On of the versus please commercial payers prescribers, coverage on also comment the could number Medicare and commercial you

Brendan Delaney

visibility sorry. so have don't -- the Yes, we on Yes, on the prescribers.

therapy to institutions, patient As lose we including the with level. vials visibility levels, IV shipped the once the you know, from many distributors are the in an

have the the have don't we of is And then we second level, that weeks, payer institution have ordered. first prescriber type in the X question we was on So mix commercial information. patient best there level the and institutions or between Medicare? reported level your which XX

Ahu Demir

correct. That's Brendan. Yes,

Brendan Delaney

Yes.

sense. it's the Keep under the with on nature driven the on range it's XX% the But difficult PEComa, as very without we've The they're the XX% commenting would are weeks, of that's say mix, the Medicare. makes also that in in remarks, the place, and the how from maybe by by been XX, mind, quickly payer mentioned response in is is it have age as payer, I mix what where who So prepared snapshot. as commercial in that's females so encouraging. I the payer we to mix and to don't mix of specific around a encouraged of do. anticipated had it prevalent more payers, coverage XX% very far restrictions, we've policies policies putting stood their very but as in X in on

on it So very as payer front, positive well. the looks

Ahu Demir

other And up are My question X. many on how -- open? are PRECISION year? the is currently What additional is sites many how sites open we expecting this to

Neil Desai

this Ahu, answer Thanks, question, would to like Yes. that you is Neil. Loretta, please?

Loretta Itri

Currently, United open in and the clinicaltrials.gov have look Sure. here see update can are website. you we periodically. on they X We sites the a States, who and that take

open year. to is that of Oncology, States And augmented by the XX here by U.S. centers end goal least of be major our the in United partnership cancer with Our the course, cetera. at will et

intention that achieving that. our So we is every we're target, goal, on and have of and

Ahu Demir

[indiscernible] FGFRX presentation, have FGFRX urethral AACR I At question. combinations. Just more of curious strategy elaborate disclosed are curious specifically you I'm and the if since they the one more on your could comments. cancer? on that, at combination may, I inhibitor were last If specific to just

Neil Desai

Yes.

occur. which to TSCX relevant one. is was that XX,XXX. the is It that. and on other Overall, total can can patients this the the they were TSCX we the we the as about take at looked -- of U.S., looking a terms analyze incidence Again, that TSCX of co-mutations for type key the of that note small of I in combination some suggestion like population. mutations the information in be Neil. presented other we an interesting future we AACR at annual strategies basis -- the also will therapies, alterations the But given strategies in -- number there that is percent was TSCX, in So that presentation,

combinations finding us So get we very finalized of types our can that populations presentation is of many that the can combination along and ongoing may be there's we with interesting use in into. of we drug? example, highly certainly But that and yet, which data future. evaluation that haven't for drugs helps that as that process relevant look in But

Operator

Sandler. next Our with Joe Piper Catanzaro question comes from

Joseph Catanzaro

first EAP progress rest us here. commercially. you help forward Maybe demand think Congrats on the pace still the of one transition about moving patients the launch. the if as year and think as there we Wondering are the well about to left could of patient whether And the on any maybe of FYARRO that that following pent-up sort starts experienced? need how you to new this make speak should

Neil Desai

Yes. like Joe. Brendan, you Thanks, to take that, would please?

Brendan Delaney

appreciate I necessarily I you you as complexity predictions it's really point, because probably at Joe, early -- this the to multiple question. levels appreciate. and Yes. It's as don't know, of any want there's make can kind of here

start. good I think a to off we're

I have come think that. new that to some we expect some the duration on -- of the -- patients that have over early on,

as the for as patient So remainder that play the well coming out new year in. demand of obviously will

that successfully coming in. AMPECT don't as the confident demand EAP we were the XXX% we the any with patients, patients necessarily pretty majority visibility, we're far As pent-up from that but by have or the EAP we transitioned of additional describing. and feel either expect that wouldn't Same those centers,

early they that and looks the pretty Again, -- I what available be on are to from November little year. estimates. rest think drug quickly. to were for was the for waiting patients market to February, like on in It's a that's comment and of building those the the got it

we're by and underlying said, at happens to ultra-rare demand think state what disease. given we're don't seeing, a I steady PEComa, encouraged we're in able predict As nature but I the what of the

helps. So I that hope

Joseph Catanzaro

Maybe follow-up helpful. another Yes. here. no, No, that's

mentioned guys advice had an process. scientific you last going EMA think you that were I through

what where of sort EMA Just a wondering are you around are potential filing? guys your And current there? expectations

Neil Desai

Yes, I can Joe, one. this Neil. that take is

scientific we before, backed in times later that we've And very of probably later as and just are we that fall, the receive up half, So the the in the indicated second that in EMA. on yes, based process. several expect advice they're terms process. to They've of mentioned timing in backup

expect we that later So hard would that fall, gotten advice. when, exactly have in we but to predict the

So we can following that. update

Joseph Catanzaro

Precision and you Okay. the And patients squeeze I could or not? the and for is if if in maybe wondering TSCX, ability maybe one experience Got alteration screening any comments early confidently TSCX X. call on if then on pathogenic I'm have it. your early to just

Neil Desai

I'll to pass Loretta. it then and Yes. on comment

in since to patients reviewer. screen not process So add through But we central early. can we at please? any information go screening, would of standard that, terms anything sure provide the point to have the very then that this like NGS a and is I'm you the Loretta,

Loretta Itri

I'm in on question are is, not what No, has NGS really all virtually TSCX clear a but the and reports. problem. TSCX not included routinely it been

it enables around we're or very the own the point. inactivating abnormality So The quickly. not our find asking, a NGS that of issue reviewer question sheet or or by We them fine-tuned actually this a is the we so participating that not TSC have [Technical turn not way cheat confirm indeed whether of the maybe whether can their inactivating, pretty can trending you're report Difficulty] to sort on handle provided I that hard it's of to institutions to is them. think, machine are translate central our we they we and them all at

of So point, going does any not it's appear kind that, to for us. be like at this obstacle

Operator

[Operator Instructions].

with next Song Our Jefferies. question from Roger comes

Jiale Song

Okay. Great. questions of couple us. A initial Congrats from for launch. the

imagine? facilitate reimbursement to this What the of over gross And time? J-code? is the steady And do reimbursement? the that evolve will the question will the you net to sequentially, is before J-code process of you kind growth So what kind state expect current first how would the how is,

Neil Desai

joining. Yes. Roger, for Thanks this is Neil.

a were there. little soft You

it So we questions little again, so repeating if mind A sure make clearly? bit heard louder? just we you don't the

Jiale Song

Yes.

the about voice. Sorry

hear So now? you can me

Neil Desai

Yes, better. I think that's

Jiale Song

Great. Okay.

facilitate that how is So And over to And What that process? current your look is, do will you is gross steady evolve the state of what future the specifically, will the question time? reimbursement? a to to kind reimbursement growth like will the J-code the how the net expect model?

Neil Desai

would that like well. that, Okay. take We hear could please? you Brendan, to

Brendan Delaney

Roger. Yes,

with policies on the label, a think that streamlines to a with, just prior which the process, have right? lot mentioned, I as it So really on positive payers authorization I restrictive. J-code, of come is not currently,

done held also the Because -- of may miscellaneous about that their as this for through therapy. especially setting, is drug on confused prescribers, if leaves the and get it what to the far some things the temporary code, J-code, getting the Medicare and kind reimbursement think side time lot in a is, it to uneasy up, of sometimes a patients lot as for get the a creates right? and billing a community get on and I of burden prescribers

because you as assigned So any far possible of J-code don't that But -- type in what any on just more the and the we've a well launch place. it's normal, process I to with has and miscellaneous on does much have time. getting all and that, with we've earliest the we've think for it think J-code. seen at specific this the oncology therapy. very that for we're so I risk, of as the obviously executed And is don't it permanent execution in process an FYARRO J-code Roger, apply perceived code current very streamlined is There's code for specific well. executed IV

any haven't field. heard obstacles any We seen or in pushback the

reimbursement in even gross did seamlessly, comment -- connect of of in related work early majority is the our well? you academic they me that the want resources Neil, days the process, process have And more to I part to, the question medical a then, on of is centers, use the launch. make the as on, may to lot expected Now early which and mentioned, as be

Neil Desai

on, he goes Go and get else Yes. what time as don't we XX% see hopefully, for to right the estimate. needs safe GTN probably I think XX% Roger, estimate is But And anything add, at if a within but Scott safe somewhere this ahead. I certainly now, we'll think XX% looks think Yes, a I better and know to to range if between Scott, do estimate that. you can point. I estimate And is information like. probably XX% now, that have add?

Scott Giacobello

it ultimately end really it how dependent where with say yes, than everything up. I we obviously it's commercial said will add will probably nothing evolve, on over other No, Brendan out on Roger, time. agree think to Yes. to hard how the mix to say But shakes

Jiale Song

can provided estimated you really you Okay. the Great. squeeze whole about asked around patients Yes, get overall you a just the an look way activating but Maybe mutation, have what get to that one time like? the like? all within screening some final you XX get does good patient enrollment, you And I and PRECISION. think diagnosis hours, them line send specifically, time report, maybe curious this diagnosed, time process just and understand definitively look line just line the do the the to NGS I in TSCX when say for color from the turnaround. consent, the TSCX, can

Neil Desai

you line the like patient question, Yes. essentially or question gets drug? the would clear the the you time just all? think time on of the Roger. from to on Were the officially receive Thanks, on to the first study comment question? I was Loretta, consent

Loretta Itri

really consent, the all the for far identified They as have Well, qualified criteria. of quite the been by patient get the is time you having along. inclusion, abnormality. They've exclusion

who most we say seriously for short, these patients, you I the the to X being I to goes from study. patients the X what's part, patient on sent But before to never ill, weeks are it's time say, So just happen. relatively can would going know actually would

around, infection, back COVID with days. so XX And will another a they get COVID sometimes puts that it and

X if X to know we're so But that So X, seeing helpful, I it's range. general, don't what that's in in variable would say that's variable. -- about I far. weeks, highly but

Operator

Neil back Thank you. At comments. Desai over turn closing Dr. to would to this the I for like call time,

Neil Desai

as future, much very then for can we company. of the we behalf again investors I forward at any with thank and joining you continue providing necessary for updates the On the really analysts We the thanks and call in Aadi, team would call joining, today. close the the entire value now. like to in you. and and certainly to progress And look build Thank interacting to

Operator

today's does teleconference. conclude you. This Thank

at your may this participation. lines You day. disconnect your Have time, great and thank a for you

Aadi Bioscience (AADI) 12 May 222022 Q1 Earnings call transcript